QbDVision Secures $13M in New Financing to Accelerate Digital CMC Transformation and Product Lifecycle Management for Enterprise Pharma and Biotech

QbDVision 获得 1300 万美元新融资，加速推动企业制药和生物技术的数字 CMC 转型与产品生命周期管理。

Funding co-led by Northpond Ventures and S3 Ventures, positions QbDVision to build on the momentum generated through top-tier enterprise customer acquisitions and successful global deployments

Northpond Ventures 和 S3 Ventures 联合领投，使 QbDVision 能够利用顶级企业客户获取和成功的全球部署所产生 momentum 进一步发展。

AUSTIN, Texas, May 1, 2025-- QbDVision® Inc., the leading Digital CMC platform (Chemistry, Manufacturing, and Controls) for the life sciences industry, today announced the close of $13 million in new financing, bringing the total of its Series A funding to $28 million. This investment was fueled by enterprise customer growth, successful global deployments and increased demand for its category-defining Digital CMC platform.

德克萨斯州奥斯汀，2025年5月1日——QbDVision® Inc.，生命科学行业的领先数字CMC平台（化学、制造和控制），今天宣布完成了1300万美元的新融资，使其A轮融资总额达到2800万美元。这一投资得益于企业客户的增长、成功的全球部署以及对其定义类别的数字CMC平台需求的增加。

Today, their customers include three of the top six global pharma and biotech companies. The round was co-led by prior investors Northpond Ventures and S3 Ventures, along with Create Health Ventures, and other company insiders..

今天，他们的客户包括全球前六大制药和生物技术公司中的三家。此轮融资由早期投资者 Northpond Ventures 和 S3 Ventures 共同领投，Create Health Ventures 以及其他公司内部人士参与。

This financing will enable QbDVision to expand its commercial operations and accelerate its mission to establish Digital CMC as a strategic knowledge foundation for the future of drug development, helping organizations better manage complexity, drive operational excellence, and unlock AI-powered innovation..

这笔资金将使 QbDVision 能够扩展其商业运营，并加速其将数字 CMC 建立为药物开发未来战略知识基础的使命，帮助组织更好地管理复杂性、推动运营卓越，并释放人工智能驱动的创新潜力。

“CMC is now center stage as a strategic priority for drug developers, and the need for digital transformation in this area has never been greater,” said Yash Sabharwal, President, CEO, and Co-Founder of QbDVision. “With global supply chains in flux, regulatory expectations evolving, and new therapeutic modalities becoming more complex, biopharma companies must modernize their CMC operations to remain competitive.

“CMC如今已成为药物开发者的一个战略重点，该领域对数字化转型的需求空前强烈，”QbDVision总裁、首席执行官兼联合创始人Yash Sabharwal表示。“在全球供应链不断变化、监管期望逐步演变以及新型治疗方式日益复杂的情况下，生物制药公司必须实现CMC运营的现代化，以保持竞争力。”

QbDVision’s platform gives them the structured and contextualized knowledge they need to move faster, innovate smarter, and navigate uncertainty with confidence.”.

QbDVision的平台为他们提供了结构化和情境化的知识，使他们能够更快地行动、更明智地创新，并自信地应对不确定性。"

Since its founding, QbDVision has enabled a fundamental shift required for Biopharma digital transformation. A movement away from siloed, document-centric legacy workflows and towards an integrated platform where CMC data is converted into a strategic knowledge asset. QbDVision is the force that can finally bring down the old barriers between teams, sites, organizations, and regulatory agencies.

自成立以来，QbDVision 实现了生物制药数字化转型所需的深刻变革。它推动人们摆脱孤立的、以文档为中心的传统工作流程，转向一个将 CMC 数据转化为战略性知识资产的集成平台。QbDVision 是一股能够最终打破团队、地点、组织和监管机构之间旧有障碍的力量。

By structuring, curating, and linking this data captured throughout the product lifecycle, companies leverage a shared source of truth to accelerate development and manufacturing timelines, improve regulatory readiness, and lay the foundation for AI-driven innovation..

通过构建、策划和链接在整个产品生命周期中捕获的数据，企业利用共享的真实数据源来加快开发和制造时间表，提高监管准备度，并为人工智能驱动的创新奠定基础。

'QbDVision is addressing one of the most overlooked areas in biopharma digitalization. While discovery and clinical development have seen tremendous innovation, CMC has remained largely stagnant,” said Paxton Major, Managing Director at Northpond Ventures. “Their innovative platform and vision can fundamentally alter how our industry executes, helping companies lay the digital knowledge foundation for intelligent, AI-powered pharma operations.

“QbDVision正在解决生物制药数字化中最容易被忽视的领域之一。虽然药物发现和临床开发已经看到了巨大的创新，但CMC领域在很大程度上仍然停滞不前，”Northpond Ventures的董事总经理Paxton Major表示。“他们创新的平台和愿景可以从根本上改变我们行业的执行方式，帮助企业为智能化、AI驱动的制药运营奠定数字知识基础。”

In today’s environment, with heightened pressures around manufacturing resilience and regulatory readiness, these capabilities are essential and facilitate the opportunities AI presents in accelerating the development of much-needed new medicines.'.

在当今环境下，制造弹性和监管准备方面的压力日益增加，这些能力至关重要，并且有助于利用人工智能加速开发急需的新药。

Digital CMC: Empowering a smarter, more agile future for biopharma

数字CMC：赋能生物制药更智能、更灵活的未来

As the biopharmaceutical sector adapts to challenges ranging from supply chain disruption to globalization trends reversing in favor of onshoring, companies urgently need ways to manage and transfer critical CMC knowledge more effectively. Regulatory bodies also call for structured, transparent CMC data in future digital submission and review processes..

随着生物制药行业适应从供应链中断到全球化趋势逆转（转向支持本土化）等挑战，公司迫切需要更有效地管理和转移关键的CMC知识的方法。监管机构还要求在未来的数字化提交和审查过程中，提供结构化、透明的CMC数据。

By delivering an intelligent, structured approach to managing CMC data and workflows digitally, QbDVision is helping companies improve operational efficiency and prepare for a future where AI-driven methods will dominate drug development and manufacturing.

通过提供一种智能化、结构化的数字化管理CMC数据和工作流程的方法，QbDVision正在帮助企业提高运营效率，并为未来AI驱动的方法主导药物开发和制造做好准备。

“Just as AlphaFold required structured, curated scientific information to build powerful predictive models to unlock the power of AI in drug development, the predictive CMC models of the future will require the trustworthy and highly contextualized CMC knowledge that QbDVision delivers,” said Sabharwal..

“正如AlphaFold需要结构化、精心策划的科学信息来构建强大的预测模型，以释放人工智能在药物开发中的力量一样，未来的预测性CMC模型将需要QbDVision所提供的可靠且高度情境化的CMC知识，”Sabharwal说。

For more information, please visit: www.qbdvision.com/structured-platform.

有关更多信息，请访问：www.qbdvision.com/structured-platform。

About QbDVision

关于QbDVision

QbDVision is a structured, cloud-based platform designed to empower teams with unified knowledge of their product and manufacturing process, while automating key development workflows throughout the entire product lifecycle journey. Unlike other traditional product lifecycle management (PLM) solutions, QbDVision’s Digital CMC platform is purpose-built for biopharma organizations to accelerate the development of life-changing therapies as they transition from R&D to Commercial Manufacturing.

QbDVision 是一个结构化的云平台，旨在为团队提供关于其产品和制造过程的统一知识，同时在整个产品生命周期中实现关键开发工作流程的自动化。与其他传统的产品生命周期管理 (PLM) 解决方案不同，QbDVision 的数字 CMC 平台专为生物制药组织打造，帮助他们在从研发转向商业制造的过程中加速开发生命改变疗法。

Teams can now leverage robust CMC knowledge that provides real-time guidance for enhanced data-driven decision making and streamlines complex operational workflows (e.g. tech transfer) that reduces cycle times, while ensuring quality and compliance. To learn more, please visit QbDVision.com or LinkedIn..

团队现在可以利用强大的CMC知识，提供实时指导，以增强数据驱动的决策能力，并简化复杂的操作流程（例如技术转移），从而缩短周期时间，同时确保质量和合规性。欲了解更多信息，请访问QbDVision.com或LinkedIn。

Contact:

联系：

Media Contact:

媒体联系人：

Eric Skivington

埃里克·斯基文顿

eric.skivington@qbdvision.com

eric.skivington@qbdvision.com